- Home
- SIBN vs RLAY Comparison
SIBN vs RLAY Comparison
Compare SIBN & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIBN
- RLAY
- Stock Information
- Founded
- SIBN 2008
- RLAY 2015
- Country
- SIBN United States
- RLAY United States
- Employees
- SIBN N/A
- RLAY N/A
- Industry
- SIBN Medical/Dental Instruments
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SIBN Health Care
- RLAY Health Care
- Exchange
- SIBN Nasdaq
- RLAY Nasdaq
- Market Cap
- SIBN 733.0M
- RLAY 610.3M
- IPO Year
- SIBN 2018
- RLAY 2020
- Fundamental
- Price
- SIBN $17.25
- RLAY $3.74
- Analyst Decision
- SIBN Strong Buy
- RLAY Strong Buy
- Analyst Count
- SIBN 5
- RLAY 11
- Target Price
- SIBN $24.40
- RLAY $18.40
- AVG Volume (30 Days)
- SIBN 345.1K
- RLAY 2.3M
- Earning Date
- SIBN 08-04-2025
- RLAY 08-05-2025
- Dividend Yield
- SIBN N/A
- RLAY N/A
- EPS Growth
- SIBN N/A
- RLAY N/A
- EPS
- SIBN N/A
- RLAY N/A
- Revenue
- SIBN $176,601,000.00
- RLAY $7,679,000.00
- Revenue This Year
- SIBN $19.48
- RLAY $17.59
- Revenue Next Year
- SIBN $16.86
- RLAY N/A
- P/E Ratio
- SIBN N/A
- RLAY N/A
- Revenue Growth
- SIBN 22.60
- RLAY N/A
- 52 Week Low
- SIBN $11.70
- RLAY $1.78
- 52 Week High
- SIBN $20.05
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- SIBN 46.79
- RLAY 58.29
- Support Level
- SIBN $16.39
- RLAY $3.47
- Resistance Level
- SIBN $17.82
- RLAY $3.97
- Average True Range (ATR)
- SIBN 0.62
- RLAY 0.20
- MACD
- SIBN -0.02
- RLAY -0.00
- Stochastic Oscillator
- SIBN 34.68
- RLAY 54.00
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).